News Related to In Vivo Chimeric Antigen Receptor T-Cell Technology

Related coverage linked through entity extraction aliases.

Eli Lilly Reports Strong 2025 Clinical Trial Results, Acquires Orna Therapeutics

Feb 14, 2026

Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.

Eli Lilly Expands Pipeline with $2.4B Orna Acquisition and AI Drug Development Push

Feb 14, 2026

Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.